不同频率电针治疗偏头痛门诊患者头痛发作的比较效果:随机安慰剂对照试验研究方案
本研究为随机、单盲、安慰剂对照三臂试验,计划纳入144例偏头痛门诊患者,随机分配至2 Hz电针组、100 Hz电针组和安慰剂对照组。试验持续20周,包括4周基线期、4周治疗期(共12次治疗)和12周随访期,主要结局为随机化后第4周末过去4周偏头痛发作频率。
要点
- 试验比较2 Hz与100 Hz电针及安慰剂对偏头痛发作频率的影响。
- 主要结局为第4周末过去4周偏头痛发作频率。
- 计划招募2021年6月1日开始,2023年5月31日结束。
核心结论
- 旨在明确电针治疗偏头痛发作的优势频率。
研究设计与样本
- 随机、单盲、安慰剂对照三臂试验,计划纳入144例偏头痛门诊患者。
- 随机分配至2 Hz电针组、100 Hz电针组和安慰剂对照组。
- 试验持续20周:4周基线期、4周治疗期(12次治疗)和12周随访期。
关键数值与推荐
- 主要结局:随机化后第4周末过去4周偏头痛发作频率。
- 次要结局:第8、12、16周末过去4周发作频率、头痛天数、布洛芬剂量、VAS评分、SAS评分、SDS评分和MSQ评分。
- 安全评估、依从性和盲法评价在第16周末进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Headache attacks severely impaired life quality and increase the economic burden of migraineurs. Electroacupuncture (EA) has been used worldwidely to treat several pain-related diseases including migraines. However, whether EA with low or high frequency exerts a distinct analgesic effect remains unknown and needs further study. METHODS/DESIGN: This study is a randomised, single-blinded, placebo-controlled trial with three parallel arms. A total of 144 migraine outpatients will be randomly allocated to the 2 Hz EA group, 100 Hz EA group and placebo control group. The duration of the trial is 20 weeks, including a 4-week-long baseline assessment period (weeks - 4-0), a 4-week-long treatment period (weeks 1-4) and a 12-week-long follow-up period (weeks 5-16). Twelve treatment sessions will be performed over a 4-week period (weeks 1-4). The primary outcome will be measured by the frequency of migraine attacks in the past 4 weeks at the end of week 4 post-randomisation. The secondary outcome will be measured by the frequency of migraine attacks in the past 4 weeks at the end of weeks 8, 12 and16 post-randomisation; number of days with migraine; dosage of ibuprofen; the scores of visual analogue scale (VAS); Self-Rating Anxiety Scale (SAS); Self-Rating Depression Scale (SDS); and Migraine Specific Quality of Life questionnaire (MSQ) in the past 4 weeks at the end of weeks 4, 8, 12 and 16 post-randomisation. Safety assessment, compliance and blinding evaluation will be carried out at the end of week 16 post-randomisation. DISCUSSION: The recruitment will be started on 1 June 2021 and expected to finish on 31 May 2023. We aimed to clarify the dominant frequency of EA on headache attacks in a migraineur. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR-1800017259 . Registered on 20 July 2018.
引用
- Nie N, Chen L, Li T, et al. Comparative effect of electroacupuncture with different frequency on headache attacks in migraine outpatients: study protocol for a randomised placebo-controlled trial. Trials. 2021. PMID: 34301299. doi:10.1186/s13063-021-05429-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。